Alnylam Pharmaceuticals ALNY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AMVUTTRA | $2.89B+25.1% | $2.31B+30.4% | $1.77B+31.7% | $1.35B+24.1% | $1.09B+11.8% | |
| GIVLAARI | $315.91M+2.4% | $308.49M+7.7% | $286.34M+1.0% | $283.51M+7.1% | $264.78M+3.5% | |
| ONPATTRO | $143.78M-16.8% | $172.79M-12.4% | $197.21M-5.4% | $208.42M-10.6% | $233.13M-7.8% | |
| OXLUMO | $200.67M+4.8% | $191.44M+3.3% | $185.36M+7.3% | $172.75M+3.8% | $166.49M-0.3% | |
| Transaction price by Product | ||||||
| Research Services Obligation | $402M— | —— | —— | —— | —— | |
| Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements by Product | ||||||
| Vutrisiran | $88.42M+13.8% | $77.71M— | —— | —— | —— | |
| Zilebesrian | $21.12M0.0% | $21.13M— | —— | —— | —— | |
| Interest Expense by Product | ||||||
| Vutrisiran | $85.23M+4.3% | $81.74M— | —— | —— | —— | |
| Zilebesrian | $6.99M+2.0% | $6.85M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alnylam Pharmaceuticals break its business down?
- Alnylam Pharmaceuticals (ALNY) reports total revenues by product across 4 parts — AMVUTTRA, GIVLAARI, ONPATTRO and OXLUMO. Each is extracted from the segment footnotes and tracked over time.
- Where does Alnylam Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alnylam Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
